CRIS Current Research Information System

OTTAVIANI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.708
NA - Nord America 9.267
EU - Europa 7.407
AF - Africa 615
SA - Sud America 480
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 9
Totale 27.502
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.148
VN - Vietnam 2.851
CN - Cina 2.453
SG - Singapore 2.444
GB - Regno Unito 2.056
SE - Svezia 1.198
IT - Italia 936
DE - Germania 899
HK - Hong Kong 574
FR - Francia 477
IN - India 426
RU - Federazione Russa 361
BR - Brasile 326
IE - Irlanda 267
NL - Olanda 236
KR - Corea 211
UA - Ucraina 174
ZA - Sudafrica 173
JP - Giappone 168
TG - Togo 146
FI - Finlandia 141
EE - Estonia 139
GR - Grecia 104
NG - Nigeria 104
CH - Svizzera 101
CI - Costa d'Avorio 93
JO - Giordania 82
BG - Bulgaria 81
CA - Canada 76
AR - Argentina 67
PH - Filippine 67
BE - Belgio 59
SC - Seychelles 50
BD - Bangladesh 47
IR - Iran 46
TH - Thailandia 44
AT - Austria 42
IQ - Iraq 42
PL - Polonia 42
TR - Turchia 39
ID - Indonesia 36
TW - Taiwan 28
UZ - Uzbekistan 27
ES - Italia 25
MX - Messico 24
EC - Ecuador 21
SA - Arabia Saudita 20
MY - Malesia 19
PK - Pakistan 16
PE - Perù 14
PY - Paraguay 13
AU - Australia 12
CL - Cile 12
EG - Egitto 11
LB - Libano 11
VE - Venezuela 11
RO - Romania 10
CO - Colombia 9
HR - Croazia 8
KE - Kenya 8
LT - Lituania 8
EU - Europa 7
PT - Portogallo 7
TM - Turkmenistan 7
ET - Etiopia 6
KZ - Kazakistan 6
MA - Marocco 6
MU - Mauritius 6
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 5
IL - Israele 5
OM - Oman 5
TN - Tunisia 5
AL - Albania 4
BB - Barbados 4
MK - Macedonia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
CY - Cipro 3
DK - Danimarca 3
GY - Guiana 3
KG - Kirghizistan 3
PS - Palestinian Territory 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
DZ - Algeria 2
GT - Guatemala 2
HN - Honduras 2
KH - Cambogia 2
LV - Lettonia 2
NO - Norvegia 2
PA - Panama 2
SN - Senegal 2
Totale 27.480
Salva come PNG Salva come JPEG
Città #
Southend 1.887
Singapore 1.692
Ashburn 977
Dong Ket 917
Chandler 841
Fairfield 820
Hong Kong 545
San Jose 506
Houston 465
Ho Chi Minh City 442
Wilmington 408
Hefei 395
Beijing 389
Woodbridge 388
Seattle 381
Hanoi 380
Ann Arbor 375
Princeton 319
Santa Clara 309
Cambridge 295
Dublin 266
Boardman 215
Bologna 184
Westminster 164
Seoul 163
Lauterbourg 160
Padova 156
Lomé 146
Nanjing 146
Tokyo 145
Los Angeles 132
New York 129
Helsinki 114
Medford 111
Milan 96
Abidjan 93
Amman 81
Bern 81
Saint Petersburg 79
Jinan 78
Sofia 78
Shenyang 77
Munich 70
Abeokuta 69
Frankfurt am Main 69
Bremen 65
Haiphong 65
Buffalo 62
Hebei 62
Berlin 61
Da Nang 61
Dallas 61
Brussels 58
Jacksonville 58
Nanchang 57
Changsha 55
Redondo Beach 55
San Diego 49
Turin 49
São Paulo 46
Shanghai 43
Tianjin 42
Florence 39
Redwood City 38
Bengaluru 37
Guangzhou 36
Jiaxing 35
Falls Church 34
Zhengzhou 31
Hangzhou 29
Toronto 27
Athens 26
Orem 26
Rome 26
Hải Dương 25
Johannesburg 25
Vienna 25
Biên Hòa 24
Xi'an 24
Falkenstein 22
London 22
Paris 22
Turku 22
Amsterdam 21
Ningbo 21
Norwalk 21
Bangkok 19
Taizhou 19
Warsaw 19
Chengdu 18
Mountain View 18
Taiyuan 18
Can Tho 17
Jakarta 17
Nuremberg 17
Phoenix 17
Chicago 16
Istanbul 16
Mülheim 16
Tongling 16
Totale 17.683
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 347
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 341
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 334
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 302
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 291
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 281
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 271
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 258
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 253
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 251
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 249
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 246
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 238
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 235
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 234
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 230
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 227
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 227
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 226
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 226
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 218
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 215
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 209
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 208
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 208
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 207
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 200
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 200
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 200
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 198
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 197
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 197
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 196
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 195
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 193
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 190
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 189
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 188
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 187
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 186
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 185
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 185
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 185
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 183
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 183
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 182
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 181
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 181
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 180
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. 179
Clec12a: A new AML stem cell-associated antigen 177
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 176
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 176
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 175
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 174
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 174
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 172
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 172
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 171
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 170
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 169
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 168
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 167
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 167
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 167
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 166
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 166
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 166
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 163
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 163
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells 162
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 162
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 162
SNP array reveals a new deletion of JAK2 in AML patients 162
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 161
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 159
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 159
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 158
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 158
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 157
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 157
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 156
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 155
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 154
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 154
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 154
You have accessA New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 154
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 154
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 153
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 152
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 150
Totale 19.721
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.789
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.789
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.481 0 0 0 0 0 0 0 0 0 112 108 1.261
2021/20223.331 357 70 216 322 329 221 58 187 150 255 597 569
2022/20233.509 416 568 174 487 225 282 107 193 569 86 254 148
2023/2024914 35 149 39 91 49 211 61 64 59 45 63 48
2024/20253.570 137 548 292 249 459 154 331 106 35 318 164 777
2025/20268.197 746 772 720 542 940 475 789 383 2.132 698 0 0
Totale 28.010